Opportunity for early entrance in an innovative company close to initiation of clinical trials utilising our in-house developed proprietary technologies, EpiTCer® and PIOR®, providing a unique personalised immunotherapy with the aim to treat solid cancer without causing significant side effects.
Cancer is one of the major causes of death world-wide. When it comes to CRC (colorectal cancer), over 1.8 million new cases and 881 000 deaths were estimated for 2018 on a global level. This corresponds to about one in ten cancer cases and deaths. For CRC patients with stage IV metastasised disease, the initial target for NEOGAP’s pTTL cell therapy product and corresponding to 25% of all incidences on a global level, the prognosis is poor with a 5-year survival of only 12-13% presenting a considerable unmet medical need.